STOCK TITAN

Director Chelsea Sierra Voss granted RSUs and stock options at Q/C Technologies (QCLS)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Q/C Technologies director Chelsea Sierra Voss reported new equity awards. On January 16, 2026, she received 212,500 shares of common stock as restricted stock units under a consulting agreement and 25,000 additional RSU shares tied to her appointment to the board. Both RSU grants vest in four equal quarterly installments if she continues providing services.

She also received an employee stock option for 212,500 shares of common stock at an exercise price of $5.097 per share, vesting quarterly on the same schedule. Following these awards, she beneficially owns 239,900 shares of common stock directly and 59,802 shares indirectly through a Roth IRA, plus 212,500 stock options.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Voss Chelsea Sierra

(Last) (First) (Middle)
1185 AVENUE OF THE AMERICAS, SUITE 249

(Street)
NEW YORK NY 10036

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Q/C TECHNOLOGIES, INC. [ QCLS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 01/16/2026 A 212,500 A $0(1) 214,900 D
Common stock 01/16/2026 A 25,000 A $0(2) 239,900 D
Common stock 59,802 I By Roth IRA
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $5.097 01/16/2026 A 212,500 (3) 01/16/2036(3) Common Stock 212,500 $0 212,500 D
Explanation of Responses:
1. Represents a grant of Restricted Stock Units ("RSUs") issued pursuant to a consulting agreement, dated January 16, 2026, by and between the Issuer and the Reporting Person (the "Consulting Agreement"). The RSUs will vest in four substantially equal installments on each quarterly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates.
2. Represents a grant of RSUs issued in connection with the appointment of the Reporting Person as director of the Issuer's board of directors. The RSUs will vest in four substantially equal installments on each quarterly anniversary of the date of grant, provided that the Reporting Person is employed by or providing services to the Issuer through the applicable vesting dates.
3. The stock options were granted pursuant to the Consulting Agreement and will vest in four substantially equal installments on each quarterly anniversary of the date of grant, provided that the Reporting Person is employed by or providing services to the Issuer through the applicable vesting dates.
/s/ Chelsea Sierra Voss 01/30/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Q/C Technologies (QCLS) report for Chelsea Sierra Voss?

Q/C Technologies director Chelsea Sierra Voss reported receiving new equity awards on January 16, 2026. She was granted restricted stock units and stock options, increasing her direct and indirect beneficial ownership in the company’s common stock and aligning compensation with ongoing service.

How many Q/C Technologies (QCLS) shares did Chelsea Sierra Voss receive as RSUs?

Chelsea Sierra Voss received 212,500 shares as restricted stock units under a consulting agreement and 25,000 RSU shares related to her board appointment. Both grants vest in four equal quarterly installments, contingent on her continuing to provide services to Q/C Technologies.

What stock option grant did Chelsea Sierra Voss receive from Q/C Technologies (QCLS)?

She received an employee stock option for 212,500 shares of Q/C Technologies common stock at an exercise price of $5.097 per share. The options vest in four substantially equal quarterly installments, conditioned on her continued employment or service to the company.

How many Q/C Technologies (QCLS) shares does Chelsea Sierra Voss beneficially own after the grants?

After the reported grants, Chelsea Sierra Voss beneficially owns 239,900 shares of Q/C Technologies common stock directly. She also holds 59,802 additional shares indirectly through a Roth IRA, plus 212,500 stock options that may be exercised in the future subject to vesting.

What are the vesting conditions for Chelsea Sierra Voss’s RSUs from Q/C Technologies (QCLS)?

The RSUs granted to Chelsea Sierra Voss vest in four substantially equal installments on each quarterly anniversary of the grant date. Vesting requires that she remain employed by, or continue providing services to, Q/C Technologies through each applicable vesting date.

Are Chelsea Sierra Voss’s option grants from Q/C Technologies (QCLS) tied to a consulting agreement?

Yes. The employee stock options for 212,500 shares were granted under a consulting agreement dated January 16, 2026. These options vest in four quarterly installments, provided she continues to be employed by or provide services to Q/C Technologies through each vesting date.
TNF Pharmaceuticals

NASDAQ:TNFA

TNFA Rankings

TNFA Latest News

TNFA Latest SEC Filings

TNFA Stock Data

9.60M
1.85M
0.01%
0.3%
3.21%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
NEW YORK